ChemicalBook >> CAS DataBase List >>4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

CAS No.
404844-11-7
Chemical Name:
4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
Synonyms
Imatinib Impurity 43;Imatinib impurities3;PDGFRα kinase inhibitor 2;Imatinib genotoxic impurity D9;Imatinib Impurity B/ Imatinib Impurity 1;4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-y...; N-[5[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]4-(3-pyridyl)-2-pyrimidine;4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide;N-[5-[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine;Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
CBNumber:
CB01176522
Molecular Formula:
C24H20ClN5O
Molecular Weight:
429.9
MDL Number:
MFCD09841001
MOL File:
404844-11-7.mol
MSDS File:
SDS
Last updated:2026-09-10 08:17:50

4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide Properties

Melting point 300°C (dec)
Density 1.329
storage temp. Keep in dark place,Sealed in dry,Store in freezer, under -20°C
solubility Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
form Solid
pka 12.99±0.70(Predicted)
color Pale Yellow to Light Beige
CAS DataBase Reference 404844-11-7

SAFETY

Risk and Safety Statements

Symbol(GHS)  Exclamation Mark (GHS07)
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338

4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide price More Price(30)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0205716 PDGFRα kinase inhibitor 2 98.95% 404844-11-7 10mg $49 2026-06-04 Buy
ChemScene CS-0205716 PDGFRα kinase inhibitor 2 98.95% 404844-11-7 25mg $81 2026-06-04 Buy
ChemScene CS-0205716 PDGFRα kinase inhibitor 2 98.95% 404844-11-7 50mg $119 2026-06-04 Buy
ChemScene CS-0205716 PDGFRα kinase inhibitor 2 98.95% 404844-11-7 100mg $179 2026-06-04 Buy
Matrix Scientific 293397 4-(Chloromethyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide 404844-11-7 250.00mg $102 2026-05-19 Buy
Product number Packaging Price Buy
CS-0205716 10mg $49 Buy
CS-0205716 25mg $81 Buy
CS-0205716 50mg $119 Buy
CS-0205716 100mg $179 Buy
293397 250.00mg $102 Buy

4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide Chemical Properties, Uses, Production

Chemical Properties

Off-White Solid

Uses

Gleevec Impurity

Synthesis

4-(Chloromethyl)benzoyl chloride

876-08-4

N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine

152460-10-1

4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

404844-11-7

1. 6-Methyl-N1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine (10.0 g, 36.0 mmol) and triethylamine (10.0 ml, 72.2 mmol) were dissolved in tetrahydrofuran (100 mL). The solution was cooled to 0 °C with stirring and kept for 10 min. 2. A solution of 4-(chloromethyl)benzoyl chloride (7.8 g, 41.4 mmol) in tetrahydrofuran (50 mL) was added dropwise. After stirring at 0 °C for 4 h, water (500 mL) was added dropwise to the reaction mixture and a pale yellow precipitate appeared. 3. The precipitate was collected by filtration, washed with water (2 x 500 ml) and dried under reduced pressure to afford 4-(chloromethyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (15.1 g, yield: 97.4%) as a light yellow solid. 4. The substance (4 g, 93 mmol) and tert-butyl piperazine carboxylate (8.8 g, 465 mmol) were dissolved in N-methyl-2-pyrrolidone (20 mL). The solution was reacted under microwave conditions at 120°C for 1 hr. 5. After cooling to room temperature, dichloromethane (50 mL) was added to the reaction mixture. The resulting mixture was extracted with 1M hydrochloric acid (20mL). The acidic aqueous phase was neutralized with sodium carbonate and then extracted with dichloromethane (2 x 50 mL). 6. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (pentane/ethyl acetate) to give 4 g of 4-(4-((4-methyl-3-((4-(4-(pyridin-3-yl)pyrimidin-2- yl)tert-butyl)amino)phenyl)carbamoyl)benzyl)piperazine-1-carboxylate (72% yield) as a yellow solid. 7. The substance (580 mg, 1 mmol) was dissolved in an ethyl acetate solution of hydrochloric acid (5 mL, 4 M). The reaction mixture was stirred at room temperature for 2 hours and then concentrated under reduced pressure to give N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(piperazin-1-ylmethyl)benzamide hydrochloride. 8. (5Z,8Z,11Z,14Z,17Z)-Eicos-5,8,11,14,17-pentaenoic acid (EPA, 0.27 g, 0.92 mmol) was substituted with HATU (0.47 g, 1.24 mmol), triethylamine (0.25 g, 2.49 mmol), and N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2 -yl)amino)phenyl)-4-(piperazin-1-ylmethyl)benzamide hydrochloride (0.4 g, 0.83 mmol) were reacted in 15 mL of dichloromethane. The reaction mixture was stirred at room temperature for 16 hours. 9. The reaction mixture was diluted with dichloromethane (100 mL). The organic layer was washed with aqueous ammonium chloride (3 x 100 mL), brine (3 x 100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography (gradient elution, 2:1 pentane/ethyl acetate to 100% ethyl acetate) to give 0.4 g of 4-((4-((5Z,8Z,11Z,14Z,17Z)-eicos-5,8,11,14,17-pentenoyl)piperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)) pyrimidin-2-yl)amino)phenyl)benzamide (62% yield).

References

[1] ChemMedChem, 2017, vol. 12, # 7, p. 487 - 501
[2] Patent: WO2014/204856, 2014, A1. Location in patent: Paragraph 0310-0311
[3] Patent: WO2006/71130, 2006, A2. Location in patent: Page/Page column 25-27
[4] Tetrahedron Letters, 2012, vol. 53, # 49, p. 6657 - 6661
[5] Patent: US9095622, 2015, B2. Location in patent: Page/Page column 33

4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide Preparation Products And Raw materials

Global Suppliers ( 109)
Supplier Tel Email Country ProdList Advantage
J & K SCIENTIFIC LTD. 18210857532 18210857532 jkinfo@jkchemical.com China 96815 76
Adamas Reagent, Ltd. 400-6009262 15618770481 yhx@titansci.com China 14098 59
Chemsky(shanghai)International Co.,Ltd. 021-50135380 shchemsky@sina.com China 32273 50
China Langchem Inc. 0086-21-58956006 China 7798 57
BOC Sciences 1-631-485-4226; 16314854226 info@bocsci.com United States 9920 65
Chengdu HappySyn Pharmaceutical Technology Co., Ltd. 85114309 18982182443 yangli@happysyn.com China 2297 55
Guangzhou Isun Pharmaceutical Co., Ltd 020-39119399 18927568969 isunpharm@qq.com China 4773 55
Hubei XinyuanShun Chemical Co., Ltd. 13971561712, 13995564702, 027-50664929 hbeixys2001@163.com China 3110 55
Bide Pharmatech Ltd. 400-164-7117 18317119277 product02@bidepharm.com China 40000 60
Quality Control Solutions Ltd. 0755-66853366 13670046396 orders@qcsrm.com China 18188 56

View Latest Price from 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Imatinib impurities3 pictures 2026-09-10 Imatinib impurities3
404844-11-7
$36.00-81.00 98.63% 10g TargetMol Chemicals Inc.
4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide pictures 2020-01-08 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
404844-11-7
$2.00 1g 98%MIN Career Henan Chemical Co

4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide Spectrum

N-[5[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]4-(3-pyridyl)-2-pyrimidine N-[5-[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide IMatinib interMediate (N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaMino)-phenyl]-4-ChloroMethyl BenzaMide) 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide N-[5-[[4-(Chloromethyl)benzoyl]amino]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine Imatinib genotoxic impurity D9 Imatinib impurity 18/4-(Chloromethyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide Imatinib Impurity 43 [2H9]-N-[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-chloromethyl Benzamide(Imatinib genotoxic impurity) Benzamide, 4-(chloromethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- 4-Chloromethyl-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-y... Imatinib impurities3 PDGFRα kinase inhibitor 2 Imatinib Impurity B/ Imatinib Impurity 1 404844-11-7 C24H20ClN5O Nucleotides and Nucleosides Bases & Related Reagents Intermediates & Fine Chemicals Nucleotides Pharmaceuticals